<DOC>
	<DOCNO>NCT00003744</DOCNO>
	<brief_summary>The purpose study see patient incurable salivary gland cancer , chemotherapy , respond Gemcitabine . The investigator try find effect ( good bad ) Gemcitabine participant salivary gland cancer . Gemcitabine show effective chemotherapy agent type cancer , include ; bladder cancer , breast cancer , certain type lung cancer , ovarian cancer , pancreas cancer . Gemcitabine yet study efficacy subject salivary gland cancer general chemotherapy drug show ineffective far population .</brief_summary>
	<brief_title>Gemcitabine Treating Patients With Advanced Salivary Gland Cancer That Can Be Removed During Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate response rate patient incurable salivary gland cancer treat gemcitabine . - Evaluate time progression toxicity therapy patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 28 day course . Patients receive minimum 2 course treatment . Patients may continue treatment absence disease progression unacceptable toxicity . Patients follow every 2 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic diagnosis follow malignancy originate salivary tissue : adenoid cystic carcinoma , mucoepidermoid carcinoma , acinic cell carcinoma , malignant mixed tumor , polymorphous low grade adenocarcinoma , undifferentiated carcinoma , squamous cell carcinoma , adenocarcinoma . Patients must incurable basis unresectable local distant disease determine patient 's surgeon potentially curable radiation therapy determine radiation oncologist . Patients may receive radiation site follow caveat : site use evaluation response either previously irradiate show progression disease post radiation time interval one month since site radiate . Patients must ECOG performance status less 3 . Patients must least unidimensionally measurable disease document within one month initiation treatment . Measurement may physical exam radiologically . Patients must willing able go process inform consent . Patients must life expectancy exceed 3 month . Patients must least 18 year old . Patients must adequate organ function define follow test perform within 14 day therapy initiation : Absolute neutrophil count &gt; 1999 cell x 10 6/L Platelet count &gt; 99,999 cell x 10 6/L Hemoglobin &gt; 8.5 gm/dl HCT &gt; 25 % Serum creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) creatinine clearance measure 24 hour urine collection least 50 % institutional low limit normal . Total bilirubin &lt; 2 x institutional ULN AST ( SGOT ) &lt; 2 x institutional ULN * *If document liver involvement cancer , may &lt; 5 x institutional ULN Alkaline Phosphatase &lt; 5 x institutional ULN If document bone liver involvement cancer , upper limit restriction . Exclusion Criteria Patients must receive cytotoxic chemotherapy salivary gland cancer . Previous immunologic , hormonal , homeopathic , natural , alternative medicine therapy acceptable provided treatment end great 28 day prior protocol therapy . Previous radiotherapy salivary cancer acceptable provide treatment end great 28 day prior protocol therapy . Patients must receive form ( include radiotherapeutic , immunologic , hormonal , homeopathic , natural , alternative medicine ) antineoplastic therapy gemcitabine participate study . Patients must history invasive neoplasm within three year trial entry , except curatively treat nonmelanoma skin cancer cervical cancer . Pregnant breast feeding woman eligible study . No pregnancy test require . Women childbearing potential must counsel use effective birth control prior participation study . Patients significant active illness ( e.g . congestive heart failure , COPD , uncontrolled diabetes , AIDS ) eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>salivary gland acinic cell tumor</keyword>
	<keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
	<keyword>salivary gland poorly differentiate carcinoma</keyword>
	<keyword>salivary gland anaplastic carcinoma</keyword>
	<keyword>salivary gland malignant mixed cell type tumor</keyword>
	<keyword>salivary gland adenoid cystic carcinoma</keyword>
</DOC>